LOPRESSOR Drug Patent Profile

When do Lopressor patents expire, and when can generic versions of Lopressor launch?

Lopressor is a drug marketed by Novartis and Validus Pharms and is included in four NDAs.

The generic ingredient in LOPRESSOR is hydrochlorothiazide; metoprolol tartrate. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; metoprolol tartrate profile page.

Summary for LOPRESSOR

US Patents:	0
Applicants:	2
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	26
Drug Prices:	Drug price information for LOPRESSOR
What excipients (inactive ingredients) are in LOPRESSOR?	LOPRESSOR excipients list
DailyMed Link:	LOPRESSOR at DailyMed

See drug prices for LOPRESSOR

Recent Clinical Trials for LOPRESSOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Wisconsin, Madison	Phase 2
National Center for Advancing Translational Science (NCATS)	Phase 2
Corcept Therapeutics	Phase 1

See all LOPRESSOR clinical trials

Pharmacology for LOPRESSOR

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for LOPRESSOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	LOPRESSOR	metoprolol tartrate	TABLET;ORAL	017963-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Validus Pharms	LOPRESSOR HCT	hydrochlorothiazide; metoprolol tartrate	TABLET;ORAL	018303-001	Dec 31, 1984	AB	RX	Yes	No
Novartis	LOPRESSOR	metoprolol tartrate	INJECTABLE;INJECTION	018704-001	Mar 30, 1984		DISCN	Yes	No
Novartis	LOPRESSOR	metoprolol fumarate	TABLET, EXTENDED RELEASE;ORAL	019786-001	Dec 27, 1989		DISCN	No	No
Novartis	LOPRESSOR	metoprolol fumarate	TABLET, EXTENDED RELEASE;ORAL	019786-003	Dec 27, 1989		DISCN	No	No

Expired US Patents for LOPRESSOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LOPRESSOR	metoprolol tartrate	INJECTABLE;INJECTION	018704-001	Mar 30, 1984	3,876,802
Validus Pharms	LOPRESSOR	metoprolol tartrate	TABLET;ORAL	017963-002	Approved Prior to Jan 1, 1982	3,998,790
Validus Pharms	LOPRESSOR	metoprolol tartrate	TABLET;ORAL	017963-001	Approved Prior to Jan 1, 1982	3,998,790
Novartis	LOPRESSOR	metoprolol fumarate	TABLET, EXTENDED RELEASE;ORAL	019786-004	Dec 27, 1989	4,892,739
Novartis	LOPRESSOR	metoprolol tartrate	INJECTABLE;INJECTION	018704-001	Mar 30, 1984	3,998,790

International Patents for LOPRESSOR

See the table below for patents covering LOPRESSOR around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	982140	PHENOXY-HYDROXYPROPYLAMINES AND THEIR PREPARATION
Finland	55024
Germany	58901373
Malaysia	7500161	PHENOXY-HYDROXYPROPYLAMINES AND THEIR PREPARATION
Mexico	15754	UN SITEMA PARA SUMINISTRO ORAL DE DISTRIBUCION OSMOTICA Y PROCEDIMIENTO PARA PREPARARLO.

Market Dynamics and Financial Trajectory for LOPRESSOR (Metoprolol Tartrate)

Market Overview

LOPRESSOR, known chemically as metoprolol tartrate, is a selective beta1-adrenoreceptor blocking agent used primarily to treat hypertension (high blood pressure), angina pectoris, and certain heart conditions. Here’s a detailed look at the market dynamics and financial trajectory of this drug.

Market Size and Growth

The global metoprolol tartrate market is substantial and growing. As of 2022, the market size was estimated to be around $6,101.4 million and is projected to exhibit a Compound Annual Growth Rate (CAGR) of 3.3% over the forecast period from 2022 to 2030, reaching approximately $7,931.7 million by 2030[4].

Geographical Distribution

Geographically, the market for metoprolol tartrate is diverse but dominated by certain regions. North America accounted for the highest revenue share in 2021 and is expected to continue dominating the market due to the increasing prevalence of heart diseases and the efficiency of metoprolol tartrate in treating conditions such as obstructive coronary artery disease[1].

The Asia-Pacific region is anticipated to be the fastest-growing market over the forecast period, driven by the expanding application of metoprolol tartrate for treating hypertension and angina. This growth is also fueled by the increasing use of propranolol for heart and brain ailments and the application of metoprolol tartrate in preventing migraines in this region[1].

Market Drivers

Several factors are driving the growth of the metoprolol tartrate market:

Increasing Prevalence of Hypertension

The rising prevalence of hypertension is a significant driver. According to the Centers for Disease Control and Prevention (CDC), approximately half of the adult population in the U.S. suffers from hypertension, indicating a high demand for beta-blocker medications like metoprolol tartrate[4].

Product Launches and Innovations

The market is also driven by increasing product launches by pharmaceutical companies. New formulations and indications for metoprolol tartrate are expanding its therapeutic applications, contributing to market growth[4].

Economic and Demographic Factors

The global heart failure drugs market, which includes metoprolol tartrate, is influenced by demographic factors such as the rising number of elderly individuals and lifestyle-related risk factors. These factors contribute to an increased demand for heart failure treatments, including beta blockers like metoprolol tartrate[3].

Supply Chain and Demand Dynamics

Supply chain challenges and strong demand are expected to influence the pricing of metoprolol succinate, a related salt form of metoprolol, and potentially metoprolol tartrate as well. Factors such as ongoing supply chain disruptions, tight market inventories, and the potential increase in the cost of raw materials like succinic acid can drive prices higher[2].

Economic Influences

Economic conditions also play a crucial role in the market dynamics of metoprolol tartrate. For instance, in Europe, anticipated interest rate cuts by the European Central Bank and easing inflation rates could stimulate economic activity, reduce borrowing costs, and enhance consumer spending power, potentially increasing demand for metoprolol tartrate[2].

In the United States, improved consumer confidence, driven by better economic perceptions and lower inflation, could also drive up demand for the drug, exerting upward pressure on prices. However, ongoing port congestion and labor strikes may complicate supply chains, leading to higher prices due to supply-demand imbalances[2].

Competitive Landscape

The metoprolol tartrate market is competitive, with several key players such as Novartis Pharmaceuticals, AstraZeneca, Teva Pharmaceutical Industries, Mylan N.V., and Dr. Reddy’s Laboratories. Strategic collaborations and acquisitions, such as AstraZeneca’s acquisition of CinCor, indicate a strong interest in developing cardiovascular and renal medicines, further driving market growth[3][4].

Clinical and Therapeutic Applications

Metoprolol tartrate is an effective antihypertensive agent and antianginal medication. It reduces the oxygen requirements of the heart, making it useful in the long-term management of angina pectoris. It is also effective in reducing mortality in patients with suspected or definite myocardial infarction[5].

Challenges and Restraints

Despite the growth potential, the market faces several challenges. The high cost of conducting clinical trials and research for heart failure drugs is a significant restraint. Additionally, beta-adrenergic blockade can have adverse effects in certain patients, such as those with severely damaged hearts or those subject to bronchospasm, which can limit its use in some cases[3][5].

Key Takeaways

• The global metoprolol tartrate market is projected to grow at a CAGR of 3.3% from 2022 to 2030.
• North America and the Asia-Pacific region are key markets, driven by the increasing prevalence of heart diseases and expanding therapeutic applications.
• Supply chain challenges and economic factors are expected to influence pricing and demand.
• The market is competitive, with major pharmaceutical companies driving growth through product launches and strategic acquisitions.
• Clinical and therapeutic applications of metoprolol tartrate are diverse, but the market faces challenges related to high research costs and potential adverse effects.

FAQs

Q: What is the projected market size of metoprolol tartrate by 2030? A: The global metoprolol tartrate market is expected to reach approximately $7,931.7 million by 2030[4].

Q: Which regions are driving the growth of the metoprolol tartrate market? A: North America and the Asia-Pacific region are the key drivers, with North America holding the highest revenue share and the Asia-Pacific region expected to have the fastest CAGR[1].

Q: What are the primary therapeutic applications of metoprolol tartrate? A: Metoprolol tartrate is primarily used to treat hypertension, angina pectoris, and certain heart conditions, including reducing mortality in patients with suspected or definite myocardial infarction[5].

Q: How do economic conditions influence the metoprolol tartrate market? A: Economic conditions such as interest rate cuts, easing inflation, and consumer confidence can stimulate demand and influence pricing strategies for metoprolol tartrate[2].

Q: What are the major challenges facing the metoprolol tartrate market? A: High research and development costs, potential adverse effects in certain patient groups, and supply chain disruptions are significant challenges[3][5].

Cited Sources

1. IndustryARC: Metoprolol Tartrate Market Size Report, 2022-2027
2. ChemAnalyst: Supply Chain Woes and Strong Demand Forecast to Drive Metoprolol Succinate Prices Upward
3. Emergen Research: Heart Failure Drugs Market Size, Trend, Demand Analysis Till 2032
4. Coherent Market Insights: Metoprolol Tartrate Market Size, Trends and Forecast to 2030
5. FDA: LOPRESSOR (metoprolol tartrate) tablet - accessdata.fda.gov